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received was 3 (range: 1 to 8). Resource utilization (per month) included 1.70 outpa-
tient visits (SD:1.22), 0.22 plain thorax x-rays (SD:0.29), 0.15 thorax CTs (SD:0.24) 
and 0.14 abdominal US (SD:0.22). The average duration of treatment was 16.0 
months (SD:11.6). The average costs for drugs/materials, outpatients visits and exams 
were R$106,511, R$853 and R$3,147, respectively. On average, ﬁrst line treatment 
for a MBC patient costs R$39,367 (SD: R$38,121), with an average treatment dura-
tion of 5.12 months (SD:3.96). The average treatment costs for second line treatment, 
with an average duration of 5.08 months (SD:3.23) is R$ 52.040 (SD: R$51,328). 
From the study cohort, the main types of insurance were: medical group (HMO-like) 
(41%) and insurance company (28%). The higher costs per patients were for those 
covered under insurance companies (R$144,432) and lower costs with Medical Coop-
eratives (UNIMEDs—R$93,771). CONCLUSIONS: Patients with MBC followed for 
at least one year following MBC diagnosis, result in an average cost of care of R$ 
110,512 for the Brazilian private health care system.
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OBJECTIVOS: Se realizó un estudio en Bogotá para estimar la magnitud de la carga 
de enfermedad asociada a la infección por el virus del papiloma humano (VPH) y la 
proporción potencialmente evitable con el uso de vacunas. METODOLOGÍAS: Se 
combinaron una revisión sistemática de la literatura colombiana sobre infección por 
VPH, el análisis de datos rutinarios de vigilancia de Bogotá y un análisis de costos de 
la enfermedad. RESULTADOS: Después de corregir por subregistro y mala clasiﬁ-
cación en Bogotá se registran 322 muertes por año asociadas a cáncer de cuello uterino 
que se corresponderían con 676 casos nuevos diagnosticados anuales. Esto ocasiona 
la pérdida de 1.5 años de vida por cada 1000 mujeres al año, la mayoría en mujeres 
entre los 40 y 69 años. Adicionalmente al cáncer de cuello uterino, en Bogotá se 
diagnosticarían 6084 lesiones de alto grado y 22,984 de bajo grado. El costo de la 
enfermedad ascendería a siete millones de dólares anuales aproximadamente. Se 
encontraron debilidades en el manejo de los casos con displasias o neoplasias cervi-
cales. CONCLUSIONES: El fortalecimiento de los programas de prevención de cáncer 
de cuello uterino en Bogotá permitiría disminuir de manera importante el impacto 
epidemiológico y económico de la infección por VPH en Bogotá. Se podría considerar, 
adicionalmente, la inclusión de una vacuna contra VPH pero solo incluida dentro de 
una estrategia integral de control y a un precio que pueda ser sostenible.
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OBJECTIVOS: Estimar el costo del tratamiento de los pacientes con Sarcoma de 
Tejidos Blandos en Etapa Temprana (STBET) en el Hospital de Oncología de Centro 
Médico Nacional Siglo XXI del IMSS. METODOLOGÍAS: Estudio retrospectivo de 
pacientes con STBET, quienes recibieron atención médica del 1 de enero 2003 a 31 
de diciembre de 2008 en el HO. La perspectiva del estudio es la del IMSS, se analizaron 
únicamente los costos médicos directos. La obtención de la información se realizó 
mediante un cuestionario estructurado que permitió la obtención de la información 
general y la identiﬁcación de los recursos utilizados en cada paciente durante el período 
de estudio. Se utilizó la técnica de micro-costeo empleando los costos unitarios de 
atención médica del IMSS. Se aplicó una tasa de descuento del 5%, los costos reporta-
dos están en $US del 2008. Se emplearon modelos de regresión logística para los 
análisis multivariantes de utilización de recursos censurados. Se calcularon modelos 
de análisis de la covarianza (ANCOVA) (log y no log) para analizar los costos desde 
una perspectiva del IMSS. RESULTADOS: Se obtuvo una muestra de 12 pacientes 
atendidos de STBET, la edad promedio fue de 34 años (o 17.57), 25% fueron mujeres 
y 75% hombres, el tiempo promedio de seguimiento fue de 416 días. Los costos 
 estimados promedio fueron de US$16,331, el 3% correspondió a consultas, 14% a 
cirugías, 14% tratamiento de quimioterapia, 20% análisis clínicos y estudios de gabi-
nete, 26% hospitalizaciones y 23% a otros componentes. CONCLUSIONES: Basando 
en los resultados publicados en la literatura internacional, los costos de pacientes en 
fase avanzada (utilización de recursos sanitarios) fueron menores en el grupo de paci-
entes con STBET que en pacientes en fases avanzadas.
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OBJECTIVOS: Evaluar el impacto de la progresión del cáncer de mama (CM) sobre 
los costos médicos directos (CMD) en mujeres atendidas en el Hospital de Alta 
Especialidad de Ginecología y Obstetricia (UMAGO) del Instituto Mexicano del 
Seguro Social (IMSS). METODOLOGÍAS: Cohorte retrospectiva. Incluye pacientes 
incidentes con CM, cualquier edad, atendidas entre enero 2005 a diciembre 2008. 
La sobrevida fue deﬁnida por progresión del estudio clínico y/o muerte por CM. 
Desde la perspectiva de la UMAGO, solo los costos médicos directos fueron consid-
erados (medicamentos, procedimientos diagnósticos y terapéuticos, laboratorio, 
cirugía, hospitalización, quimioterapia y radioterapia). La fuente de información 
para estimar recursos fue el expediente clínico. Los precios fueron obtenidos de los 
costos oﬁciales del IMSS. Los resultados son expresados en pesos mexicanos. Una 
tasa de descuento del 5% fue usada, se ajustó los costos a 2008. Análisis estadístico: 
Prueba U de Mann-Whitney, curvas de Supervivencia de Kaplan-Meier, y Modelo 
Generalizado Lineal. RESULTADOS: Se estudiaron 161 pacientes, edad 50 o 11 años, 
tiempo promedio de seguimiento 28 o 11 meses, 25 (16%) presentaron el evento 
(progresión/muerte). La supervivencia al 1°, 2° y 3er año fue de 90%, 78% y 65% 
respectivamente. Al comparar los costos entre progresión y quienes mantuvieron 
estables la enfer-medad se observó diferencias en: costo promedio total: $343,783.00 
vs $219,997.47 (p  0.0001); procedimientos: $24,445.96 vs $13,042.08 (p  
0.001); tratamiento farmacológico ambulatorio: $72,685.08 vs $13,218.93; hospi-
talización: $74,342.33 vs $30,021.09; Quimioterapia: $129,688.63 vs $72,058.89. 
No se observó diferencias en: consulta externa: $47,583.04 vs $43,915.88 (p  0.47); 
laboratorio: $6057.46 vs $5,341.92 (p  0.38); cirugía: $32,524.02 vs $29,132.23 
(p  0.59); y radioterapia: $16,235.52 vs $11,933.44 (p  0.38). CONCLUSIONES: 
La progresión del CM incrementa en forma signiﬁcativamente el costo promedio total 
del tratamiento. Para disminuir el impacto económico que la progresión ocasiona es 
necesario enfocarnos hacía la detección temprana de la enfermedad y tratamiento 
oportuno.
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OBJECTIVES: The purpose of this study is to document the Mexican experience in 
advanced metastatic STS treatment in Mexican Institute of Social Security, IMSS), 
focusing on the utilization of services and cost patterns associated with STS treatment. 
METHODS: The study examines the cost of care of STS from the perspective of the 
IMSS. It considers only those costs paid directly by the IMSS. We used a retrospective 
patient chart review and collected complementary cost data to describe the utilization 
of services and estimate costs of care for adult (18 years of age and above) with 
advanced metastatic STS. Patients were selected if they had at least one visit to the 
selected hospital between January 1, 2003, and December 31, 2008. Comprehensive 
data on patient sociodemographic characteristics; clinical events; use of outpatient, 
inpatient, and laboratory services; and use of medications were captured from medical 
charts using a structured questionnaire. Because of incompleteness of follow-up data 
a linear regression analysis of censored medical costs was used. All cost are reported 
in $US 2008. RESULTS: Forty-four patients were enrolled in the study and receive 
treatment for STBMA. These 32 men and 17 women were on average 42.63 years old 
(o 18.70). Average cost per patient for 462 day, the observation period, was US$13,581 
of which 3% were inpatient costs, 7% hospitalizations, 17% surgery, 19% palliative 
chemotherapy treatment, 4% no palliative chemotherapy treatment, 22% laboratory 
services and the remainder 27% others. We found statistically signiﬁcant differences 
by gender, the average cost for men was US$19,525 vs. US$12,101 for women 
(P  0.000). CONCLUSIONS: Whereas the accompanying documentation of costs in 
clinical studies is organizationally complex and very tedious, the model applied here 
offers a reliable method of quantifying the costs of the treatment of advanced meta-
static STS.
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OBJECTIVES: To assess the cost-effectiveness of two chemotherapy regimens: six 
cycles of ﬂuorouracil, epirubicin, and cyclophosphamide (FEC) vs. three cycles of FEC 
followed by three cycles of docetaxel (FEC-D) in adjuvant treatment for patients with 
early breast cancer within public health care institutions. A total of 1999 women 
received 3FEC-3D or 6FEC in a clinical trial (PACS01). Patients in FEC-D group 
experienced an 18% reduction in risk of relapse (P  0.0001) and a 27% reduction 
in the risk of death (P  0.008), at median 60 months follow-up. METHODS: Based 
on the PACS01 trial, a lifetime Markov model was developed for comparing two 
chemotherapy regimens. The cost-effectiveness criterion was the incremental cost per 
life-year gained. Beyond clinical trial time horizon, a life expectancy was assigned to 
each patient according to the health status at the end of the trial. Resource utilization 
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was identiﬁed by an expert panel of oncologists. Only direct costs were considered. 
Costs and outcomes were discounted by an annual rate of 3% (2008). A sensitivity 
analysis was performed on the risk of relapse reduction by FEC-D using the 95% 
conﬁdence intervals around the mean of the DFS hazard ratio observed in the clinical 
trial. RESULTS: Women receiving FEC-D have a greater life expectancy than those 
treated with only FEC (22.83 versus 21.97 years). The average lifetime costs are 
US$9976 for FEC-D and US$7637 for FEC. The incremental cost-effectiveness ratio 
(ICER) was US$2,378 in the base case, varying from US$1,260 to US$30,791 accord-
ing to sensitivity analysis. CONCLUSIONS: FEC-D is associated with an increase in 
life expectancy over FEC. The FEC-D regimen in comparison with FEC fell within 
acceptable ranges of cost-effectiveness. Although there is currently no ofﬁcial cost-
effectiveness threshold in Mexico, we observed an acceptable ICER for the utilization 
of FEC-D at below 3 times the Gross Domestic Product per capita of US$43,200.
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OBJECTIVES: To evaluate the cost-effectiveness of four interventions (Interferon-á 
(IFN), Sunitinib, BevacizumabIFN, Sorafenib) approved as ﬁrst-line treatment for 
mRCC in Colombia. METHODS: A Markov model was developed using 6-week 
cycles from a third-party payer perspective and a 5-year time-line; it also presumed 
that all the patients (pts) continued with active treatment until progression when it 
became acceptable to continue with a second-line treatment or best supportive care 
(BSC). Overall survival (OS) and progression-free survival (PFS) curves of IFN were 
used as reference framework; they were obtained form a published clinical trial. The 
hazard ratios (HR) for PFS and OS were estimated for comparing new generation 
medicaments with IFN. The information about frequency of use and health service 
cost units consumed in Colombia was taken from a series of 24 pts treated in 4 cities. 
Service costs were requested from an external consultant and corresponded to the 
average value billed by the EPSs, calculated from 33 sources of information which 
were representative of the country’s market. The cost of the medicaments was obtained 
from LCLC. The costs and beneﬁts were discounted annually at 3%. RESULTS: 
Sunitinib treatment was associated with a gain in life years (LY) saved, the Incremental 
cost analysis indicated a difference of 41.1 million Col$ (19,773 USD) in the average 
total cost of treatment when Sunitinib was compared to IFN; in contrast, comparing 
Sorafenib and BevacizumabINF to Sunitinib demonstrated that the average total cost 
was less for the Sunitinib by 8.3 (3,991 USD) and 104.2 million Col$ (50,155 USD), 
respectively. Additionally, the ICER by life years (LY) gained demonstrated Sunitinib’s 
simple dominance over Sorafenib and the combination of BevacizumabIFN, and 
an average by LY gained of 100.5 million Col$ (48,362 USD) compared to IFN. 
CONCLUSIONS: Sunitinib is the most cost-effective option as ﬁrst-line treatment for 
mRCC pts in Colombia.
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OBJECTIVES: Dasatinib 100 mg is the optimized and recommended initial dose for 
patients with CML in chronic phase in Mexico. However, little is known on its cost 
effectiveness when compared with recent treatment alternatives in the market such as 
nilotinib 800 mg. This study addresses this question under the Mexican health care 
perspective. METHODS: A cost utility life-time Markov model based was used to 
calculate the incremental cost per Quality Adjusted Life Year (QALY) of the compared 
therapies. The model follows patients with CML in CP considering the different phases 
of the disease progression including accelerated and blast health states. Initial best 
response as deﬁned by the START (SRC/ABL Tyrosine Kinase Inhibition Activity 
Research Trials) studies determined the pathway the patients will follow within the 
model. The researchers did not identify any clinical trials that compared dasatinib 
directly with the comparator, and therefore an indirect comparison was performed. 
For the indirect comparison all the relevant published efﬁcacy literature was used. 
Transition probabilities and QALYs were estimated from published international lit-
erature. Estimates of the use of health care resources by CML patients in Mexico came 
from a previously reported study using the Delphi Panel technique. Costs of drugs and 
other health care treatments were primarily obtained from IMSS published informa-
tion and discounted at 5% (using the recent published guidelines by the Mexican 
National Health Council). Sensitivity analysis was performed. RESULTS: The eco-
nomic evaluation revealed that dasatinib was more effective (QALY difference of 0.2) 
and less costly (-US$41,329) than nilotinib therapy. These ﬁndings were robust to 
deterministic sensitivity analysis. CONCLUSIONS: In México, Dasatinib is a cost 
effective therapy for the management of Imatinib resistant patients with CML in the 
chronic phase. Collection of long term health care efﬁcacy data will help to validate 
these results.
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OBJECTIVES: To analyze the cost-effectiveness of temozolomide in the treatment of 
newly diagnosed glioblastoma multiforme versus radiotherapy alone from the Mexican 
health care perspective METHODS: A cost-effectiveness analysis was performed based 
on a Markov model, with three health states: initial, disease progression and death. 
This model allowed us to compare the expected outcomes and costs associated with 
temozolomide compared with radiotherapy alone for a synthetic cohort of patients 
aged q55 years over a 5-year period. The model cycles every 6 months and continues 
until all patients die. The probabilities of transition between health states were 
obtained from the literature. Costs were expressed in 2008 US dollar. Outcome esti-
mates included the incremental cost-effectiveness ratio (ICER) and cost per life-year 
(LY) gained. Second-order Monte Carlo simulations were undertaken in which values 
were randomly drawn from distributions of these parameters. RESULTS: The accu-
mulated discounted effect is 1.03 LY per patient receiving temozolomide compared to 
0.93 LY for radiotherapy alone. Total lifetime medical cost was US$31,698 for 
temozolomide vs. US$30,715 for radiotherapy alone. The incremental cost-effective-
ness of temozolomide was $US 983 per life year gained. There is a 70% probability 
that temozolomide is cost-effective at a US$10,000 per life-year saved threshold and 
a slightly more than 95% probability of being cost-effective at a US$18,000 per life-
year saved threshold CONCLUSIONS: Results from these analyses suggest that in the 
Mexican setting, use of temozolomide in place of radiotherapy alone for treatment of 
glioblastoma multiforme is likely to be cost saving. These conclusions are supported 
by the use of conservative assumptions and sensitivity analyses.
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OBJECTIVES: To estimate the cost, clinical implications and cost-effectiveness of 
different screening strategies for the early detection and prevention of breast cancer 
in Colombia, that is a growing health problem in Colombia. METHODS: The course 
of women aged 40 and older who are at risk of developing breast cancer and are eli-
gible to be screened for early detection and prevention was modeled using discrete 
event simulation. Six identical cohorts of 10,000 women were simulated 100 times, 
to compare 6 different screening strategies. Age distribution of the population was 
obtained from national data in Colombia, and the risk of developing cancer was based 
on the 1998–2002 breast cancer incidence rates in Cali, Colombia. Disease progression 
parameters for women who develop cancer were obtained from published data. Only 
direct medical costs were considered; costs are reported in 2008 Colombian Pesos 
(COP) and inﬂated using the Consumer Price Index (CPI) where current costs were 
not available. Costs and life years gained were discounted at a 3% rate. Main sensitiv-
ity analyses were around the sensitivity of the mammography and the breast clinical 
exam, the breast cancer incidence rates. RESULTS: The most cost-effective strategy 
for Colombia is an opportunistic screening program with biannual mammography for 
women between 50 and 69 years and annual breast clinical exam for women between 
30 and 69 years, with a cost per life year gained per woman of COP 36,984 and a 
reduction of 28.68% in the number of cases of cancer that progress to fatal stages of 
the disease, compared with the do-nothing strategy. CONCLUSIONS: Opportunistic 
screening for breast cancer is expected to improve outcomes and save costs compared 
to the other 5 strategies. Thus, it will bring better health to Colombian women at risk 
of developing or suffering from breast cancer at a savings to the Health Authorities.
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OBJECTIVES: Due to their commonality, basal cell carcinoma can be an expensive 
cancer to manage. Imiquimod is an effective treatment for superﬁcial basal cell carci-
noma (sBCC) though cost efﬁcacy studies are lacking. This study compared the costs 
of management approaches for superﬁcial basal cell carcinoma from a third party 
perspective at 1 and 5 years. METHODS: A decision analytic model was developed 
that compared cost of imiquimod treatment versus commonly used surgical interven-
tions including surgical excision and simple excision, curettage and electrodesiccation(ED 
& C). A United States third party payer perspective was used for the analysis. Pub-
lished recurrence rates and Medicare reimbursement rates were used for modeling and 
sensitivity analyses. RESULTS: The expected ﬁve-year modeling for imiquimod 
